A Study of LY3200882 in Participants With Solid Tumors

A Phase 1 Study of LY3200882 in Patients With Solid Tumors

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Inclusion Criteria:

• The participant must have histological or cytological evidence of cancer.
• Have adequate organ function.
• Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
• Are able to swallow capsules and tablets.

Exclusion Criteria:

• Have moderate or severe cardiovascular disease.
• Have a serious concomitant systemic disorder.
• Have acute leukemia.